CD8A and neoplasm: Treatment of D35 tumor-bearing CD8−/− mice with 4H1128ζ-IL12 T cells did not compromise its efficacy compared to 4H1128ζ (median OS; not reached vs 52 days, #p = 0.001) or untreated mice (Supplementary Fig. 2).